President Trump has announced a significant shift in US trade policy aimed at bringing generic pharmaceutical manufacturing back to American shores. In a social media post, the former President revealed that starting in August 2028, generic drugs imported from overseas will face a 100% tariff unless manufacturers relocate their production facilities to the US. The move, dubbed "reshoring," is a bid to boost domestic production and create jobs in the pharmaceutical industry. Critics argue that the tariffs could lead to higher prices for consumers and stifle competition, while supporters see it as a necessary step to protect American workers and promote economic growth.
Imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers move production to the U.S., President Trump said in a social media post Tuesday. Trump wrote on Truth Social the move is aimed at "reshoring" generic pharmaceutical production in America. The tariffs amount to a "penalty" that would hit companies if they don't...
